Podcast
Nurexone Biologic, an Israeli regenerative startup, has developed a promising biologic for nerve repair called ExoPTEN. It’s a mesenchymal stem cell-derived exosome therapy loaded with siRNA, and it’s shown promising results in preclinical studies. The therapy received Orphan Drug Designation from the FDA in 2023 and is hoping to move to Phase 1 in 2026. In this interview, Dr. Lior walks us through what ExoPTEN is, the science behind its efficacy, what the preclinical results have shown, and the next steps from Nurexone Biologics.
Life Sciences Today Podcast by Healthcare IT Today. This time Danny Lieberman is with Dr. Lior Shaltiel, Founder and CEO at NurExone
Professor Michael Belkin discusses the potentially regenerative powers of ExoPTEN for glaucoma patients…
Listen as Dr. Nisim Perets explains the opportunities creating by NurExone’s technology for turning exosomes into nanodrugs
Why is fixing the spinal cord so complicated? Listen and learn as a renowned neurosurgeon describes his work, what it means to walk, and hopeful directions for the future.